REAL LIFE EXPERIENCE WITH FIRST-LINE THERAPY IN ELDERLY MULTIPLE MYELOMA PATIENTS: CONVENTIONAL OR BORTEZOMIB-BASED? DOUBLE TREATMENT OR TRIPLE TREATMENT?


Creative Commons License

Demirsoy E. T. , GEDÜK A.

TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, vol.25, no.1, pp.58-67, 2022 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 25 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.31086/tjgeri.2022.263
  • Title of Journal : TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI
  • Page Numbers: pp.58-67
  • Keywords: Multiple Myeloma, Aged, Therapeutics, CYCLOPHOSPHAMIDE, DEXAMETHASONE, CRITERIA, RISK

Abstract

Introduction: Elderly patients with multiple myeloma have shorter survival outcomes than younger patients. In this study, we aimed to compare the efficacy and toxicity profiles of conventional and bortezomib-based therapy as first-line therapy in elderly patients with multiple myeloma and to determine the prognostic factors.